Follicular lymphoma (FL) is a heterogeneous disease with varying prognosis owing to differences in clinical, laboratory, and disease parameters. Although generally considered incurable, prognosis for early and advanced stage disease has improved because of therapeutic advances, several of which have resulted from elucidation of the biologic and molecular basis of the disease. The choice of treatment for FL is highly dependent on patient and disease characteristics. Several tools are available for risk stratification, although limitations in their routine clinical use exist. For limited disease, treatment options include radiotherapy, rituximab monotherapy or combination regimens, and surveillance. Treatment of advanced disease is often determined by tumor burden, with surveillance or rituximab considered for low tumor burden and chemoimmunotherapy for high tumor burden disease. Treatment for relapsed or refractory disease is influenced by initial first-line therapy and the duration and quality of the response. At present, there is no consensus for treatment of patients with early or multiply-relapsed disease; however, numerous agents, combination regimens, and transplant options have demonstrated efficacy. While the number of therapies available to treat FL has increased together with an improved understanding of the underlying biologic basis of disease, the best approach to select the most appropriate treatment strategy for an individual patient at a particular time continues to be elucidated. This chapter considers prognostic factors and the evolving treatment landscape of FL, including recent and emerging therapies, as well as remaining unmet needs.
Advances in Treatment of Follicular Lymphoma / Luminari, S.; Trotman, J.; Federico, M.. - In: THE CANCER JOURNAL. - ISSN 1528-9117. - 26:3(2020), pp. 231-240. [10.1097/PPO.0000000000000444]
|Data di pubblicazione:||2020|
|Titolo:||Advances in Treatment of Follicular Lymphoma|
|Autore/i:||Luminari, S.; Trotman, J.; Federico, M.|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1097/PPO.0000000000000444|
|Codice identificativo ISI:||WOS:000562683600007|
|Codice identificativo Scopus:||2-s2.0-85086008683|
|Codice identificativo Pubmed:||32496456|
|Citazione:||Advances in Treatment of Follicular Lymphoma / Luminari, S.; Trotman, J.; Federico, M.. - In: THE CANCER JOURNAL. - ISSN 1528-9117. - 26:3(2020), pp. 231-240. [10.1097/PPO.0000000000000444]|
|Tipologia||Articolo su rivista|
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris